Biologics
At Zydus, Biologics research is driven by a passion for innovation and a steadfast commitment to improving health outcomes globally. Our pipeline has been strategically designed to address the diverse needs of patients across international markets, including those in low- and middle-income countries. It encompasses a broad portfolio of biosimilars, novel biologics, antibody-drug conjugates (ADCs), bispecific antibodies, and cell and gene therapies (CGTs). These therapies target a wide range of therapeutic areas, including oncology, autoimmune disorders, ophthalmology, inflammatory diseases, rheumatology, haematology, infectious diseases, and other specialty indications. Together, they underscore Zydus' commitment to expanding access to innovative, high-quality, and affordable biologic therapies, helping improve the lives of patients worldwide.
Twinrab™
Twinrab™ is a novel monoclonal antibody (mAb) cocktail targeting non-overlapping epitopes on the rabies virus glycoprotein. It is a passive immunization therapy for the post exposure prophylaxis (PEP) of rabies, particularly for Category III exposures, given in combination with rabies vaccination. Twinrab™ is intended as an alternative to plasma derived human or equine rabies immunoglobulins (HRIG/ERIG), addressing limitations related to cost, supply constraints, batch variability, and biosafety risks.
